Noonan Syndrome 11 (NS11): The MRAS-Related Form of Noonan Syndrome — A Comprehensive Disease Characterization

Disease: Noonan Syndrome 11 (NS11) | OMIM: #618499 | MONDO: 0032786 | Gene: MRAS (HGNC:7227, chromosome 3q22.3) | Category: Genetic (autosomal-dominant RASopathy)

Scope note: This report concerns Noonan syndrome 11 (NS11), the form caused by germline activating missense variants in MRAS (M-Ras/R-Ras3). It is NOT LZTR1-related Noonan syndrome and NOT any other numbered NS subtype. Because NS11 is ultra-rare (a handful of published cases), many frequency, prognosis, and management statements are extrapolated from the broader Noonan syndrome/RASopathy literature and are flagged as such.

Summary

Noonan syndrome 11 (NS11) is an ultra-rare, autosomal-dominant subtype of Noonan syndrome caused by de novo germline gain-of-function missense variants in MRAS, the gene encoding the RAS-family GTPase M-Ras (R-Ras3). It was first delineated in 2017 and confirmed in 2020, and to date only a handful of molecularly proven cases have been reported worldwide — making it less than 1% of molecularly solved Noonan syndrome (versus ~50% attributable to PTPN11). Despite its rarity, NS11 has attracted disproportionate attention because it is defined by a severe, often neonatal/infantile-onset hypertrophic cardiomyopathy (HCM) superimposed on the classic multisystem Noonan phenotype (distinctive facies, short stature, developmental delay, and variable congenital anomalies).

Mechanistically, NS11 is a textbook example of RAS–MAPK pathway hyperactivation. The recurrent hotspot substitutions — p.Gly23Val, p.Gly23Arg, p.Thr68Ile, and p.Gln71Arg — impair the intrinsic and GAP-stimulated GTP-hydrolysis activity of M-Ras, locking it in the constitutively active, GTP-bound state. Active M-Ras recruits the SHOC2–PP1c (PPP1CB) holophosphatase, which dephosphorylates the inhibitory Ser259 site of RAF, thereby amplifying signaling through the RAF–MEK–ERK cascade (and, variably, the PI3K–AKT axis). A founder variant (p.Gly23Val) drives an approximately 40-fold increase in M-Ras activation in vitro, and CRISPR-corrected patient induced pluripotent stem cell–derived cardiomyocytes (iPSC-CMs) have proven that this single variant is both necessary and sufficient to produce cardiomyocyte hypertrophy and abnormal calcium handling.

Diagnosis is achieved through multigene RASopathy NGS panels or exome sequencing (single-gene MRAS testing is inefficient given >20 RASopathy genes). Management is multidisciplinary: recombinant human growth hormone for short stature, hemostatic screening before invasive procedures, and — most notably — off-label MEK inhibition (trametinib) as an emerging targeted therapy that can reverse or attenuate the otherwise frequently lethal HCM. This report synthesizes all 15 requested disease-characteristic domains, grounded in eight confirmed findings and 61 reviewed papers.

Key Findings

Finding 1 — Activating MRAS missense variants cause NS11 with hypertrophic cardiomyopathy

NS11 was established as a distinct RASopathy through two landmark reports. Higgins et al. (2017) identified a de novo MRAS variant (p.Gly23Val) by whole-exome trio sequencing in a 15-year-old female with Noonan syndrome and cardiac hypertrophy, after screening a cohort of 109 unrelated NS-phenotype patients. Motta et al. (2020) then reported two further unrelated patients with de novo MRAS variants — c.203C>T (p.Thr68Ile) and c.67G>C (p.Gly23Arg) — both with HCM; one died neonatally of cardiac failure. Functional assays in both studies demonstrated high-level M-Ras activation resulting from impaired GTPase activity, establishing a gain-of-function mechanism.

"Targeted sequencing revealed de novo MRAS variants, c.203C > T (p.Thr68Ile) and c.67G > C (p.Gly23Arg) as causative events" — PMID: 31108500

"Functional analyses documented high level of activation of MRAS mutants due to impaired GTPase activity" — PMID: 31108500

This finding anchors the disease definition: NS11 (OMIM #618499) is caused by activating variants in MRAS (3q22.3, HGNC:7227), and is genetically and clinically distinct from LZTR1-related and all other numbered Noonan syndrome subtypes.

Finding 2 — Mechanism: mutant M-Ras enhances the SHOC2–PP1c holoenzyme, boosting RAF/MEK/ERK and PI3K-AKT signaling

The core molecular mechanism connecting M-Ras to disease was defined by Rodriguez-Viciana et al. (2006), who showed that Shoc2/Sur-8 together with the catalytic subunit of protein phosphatase 1 (PP1c) form a highly specific M-Ras effector complex that stimulates RAF by dephosphorylating the inhibitory Ser259 (S259) site on RAF proteins. Motta et al. (2020) demonstrated that NS-causing M-Ras mutants exhibit constitutive plasma-membrane targeting, prolonged non-raft localization, enhanced binding to PPP1CB and SHOC2, and variably increased MAPK and PI3K–AKT activation — showing that the disease mutants amplify precisely this effector interaction.

"M-Ras targets Shoc2-PP1c to stimulate Raf activity by dephosphorylating the S259 inhibitory site of Raf proteins" — PMID: 16630891

"enhanced binding to PPP1CB and SHOC2 protein, and variably increased MAPK and PI3K-AKT activation" — PMID: 31108500

This places NS11 firmly within the SHOC2–PPP1CB–RAF signaling module, the same axis mutated in SHOC2-related Noonan-like syndrome with loose anagen hair (NS/LAH) and PPP1CB-related Noonan-like syndrome — a striking example of pathway-level convergence.

Finding 3 — MEK inhibition (trametinib) is an emerging targeted therapy for NS-associated HCM

Because NS11 pathology is driven by RAS–MAPK hyperactivation, pharmacologic MEK1/2 inhibition is a rational targeted therapy. A growing body of case reports documents off-label trametinib reversing or attenuating severe NS-associated HCM and lymphatic disease across multiple RASopathy genotypes (RIT1, RAF1, PTPN11), and a clinical trial is now registered (NCT06555237). Chaput & Andelfinger (2024) reviewed the repurposing of trametinib and mTOR inhibitors for RASopathy HCM. In parallel, rigosertib (a dual RAS/MAPK + PI3K/AKT inhibitor) reversed HCM in RAF1-NS models.

"repurposing of medications inhibiting the RAS/MAPK on a compassionate use basis has emerged as a promising concept to improve the outcome of these patients" — PMID: 38432396

While direct trametinib data specifically in MRAS-mutant patients are not yet published, the shared downstream mechanism (MEK/ERK hyperactivation) makes this the most promising disease-modifying strategy for NS11's lethal cardiac phenotype.

Finding 4 — Variant spectrum: recurrent likely-pathogenic hotspots in a highly constrained gene

ClinVar (RefSeq NM_001085049.3) lists recurrent NS-causing missense variants classified as Likely pathogenic:

cDNA Protein ClinVar classification
c.68G>T p.Gly23Val Likely pathogenic
c.67G>C p.Gly23Arg Likely pathogenic
c.203C>T p.Thr68Ile Likely pathogenic
c.212A>G p.Gln71Arg Likely pathogenic
c.359C>T p.Pro120Leu Likely pathogenic

Of 297 MRAS ClinVar records, only these missense point variants are pathogenic/likely-pathogenic for NS (the other "Pathogenic" entries are large 3q copy-number variants unrelated to the point-mutation mechanism). Population-constraint metrics from gnomAD (ENSG00000158186, chr3:138,347,648–138,405,534) show MRAS is strongly intolerant to both missense and loss-of-function variation: missense Z = 3.16 (observed/expected = 0.555), pLI = 0.99, LoF o/e = 0.19 (4 observed vs 20.9 expected). The pathogenic residues Gly23, Thr68, and Gln71 are conserved codons that are established mutational hotspots across the RAS protein family. All reported disease variants are germline, de novo, and absent from population databases.

"Gly23 and Thr68 are highly conserved residues, and the corresponding codons are known hotspots for RASopathy-associated mutations in other RAS proteins" — PMID: 31108500

Finding 5 — Clinical phenotype and epidemiology: an ultra-rare NS subtype with disproportionately severe, early-onset HCM

NS11 shares the core multisystem Noonan phenotype but is distinguished by its severe cardiac involvement. Noonan syndrome overall affects ~1:1,000–2,500 live births (Roberts et al. 2013), is autosomal dominant, and features distinctive facies, short stature, congenital heart disease (pulmonary valve stenosis, HCM), developmental delay/learning difficulties, cryptorchidism, lymphatic dysplasia, bleeding diathesis, and renal anomalies. NS11/MRAS accounts for only a handful of reported individuals worldwide — <1% of molecularly solved NS. Reported MRAS patients uniformly presented with HCM, often with neonatal/infantile onset and severe course (including one neonatal death from cardiac failure).

"Noonan syndrome is a genetic multisystem disorder characterised by distinctive facial features, developmental delay, learning difficulties, short stature, congenital heart disease, renal anomalies, lymphatic malformations, and bleeding difficulties" — PMID: 23312968

"hypertrophic cardiomyopathy in RASopathies (R-HCM) is associated with higher prevalence of congestive heart failure and shows increased prevalence and severity of left ventricular outflow tract obstruction" — PMID: 34776080

RASopathy-associated HCM (R-HCM) shows higher rates of congestive heart failure and left ventricular outflow tract (LVOT) obstruction than sarcomeric HCM, consistent with the severe HCM-predominant presentation of MRAS cases.

Finding 6 — M-Ras biology and evolutionary conservation inform model-organism relevance

M-Ras is a RAS-family GTPase with a single orthologue conserved from nematode to human, and it evolved independently of R-Ras (Keduka et al. 2009). In ascidian, Ci-Mras is expressed in the neural complex and its knockdown perturbs FGF–Ras–MAPK-dependent neural/notochord development; mammalian M-Ras mediates NGF-induced neuronal differentiation in PC12 cells. Beyond the SHOC2–PP1c–RAF branch, M-Ras also signals via RA-GEF-2 to activate Rap1, regulating integrin-mediated adhesion (Yoshikawa et al. 2007). Disease modeling to date is primarily via patient-derived iPSC-cardiomyocytes carrying p.Gly23Val, which reproduce hypertrophy and abnormal calcium handling.

"A single Mras orthologue exists from nematode to mammalian" — PMID: 18977283

"activated M-Ras potently induced lymphocyte function-associated antigen 1 (LFA-1)-mediated cell aggregation" — PMID: 17538012

Finding 7 — p.Gly23Val causes ~40-fold constitutive activation; iPSC-CMs prove necessity and sufficiency for cardiac hypertrophy

Higgins et al. (2017; JCI Insight) performed molecular-dynamics simulations predicting that p.Gly23Val damages the effector-interaction regions and the GTP-binding site; ectopic-expression experiments revealed a 40-fold increase in M-Ras activation versus wild-type, with enhanced RAS/MAPK signaling and downstream gene-expression changes. Higgins et al. (2019; Circ Genom Precis Med) used CRISPR/Cas9 isogenic-corrected patient iPSC-cardiomyocytes to demonstrate that the variant is both necessary and sufficient to elicit hypertrophy — larger cell size, hypertrophic gene-expression changes, and impaired Ca²⁺ handling (irregular Ca²⁺ transients).

"ectopic expression experiments revealed a 40-fold increase in MRAS activation for p.Gly23Val-MRAS compared with WT-MRAS" — PMID: 28289718

"p.Gly23Val-MRAS is both necessary and sufficient to elicit a cardiac hypertrophy phenotype in iPSC-CMs" — PMID: 31638832

This is among the strongest causal evidence in any RASopathy: an isogenic-control experiment directly linking a single point variant to the defining clinical phenotype.

Finding 8 — Diagnosis and multidisciplinary management

Diagnosis of NS is clinical (van der Burgt criteria) with molecular confirmation; because MRAS is one of >20 RASopathy genes, testing uses multigene NGS panels/exome rather than single-gene tests (Tartaglia 2022). Short stature is treated with recombinant human growth hormone; a phase 3 RCT (REAL8, NCT05330325) showed once-weekly somapacitan non-inferior/superior to daily GH (height velocity 10.4 vs 9.2 cm/yr). Bleeding diathesis affects up to ~40–65% of NS patients — partial factor XI/VII deficiency, platelet dysfunction, and shear-related acquired von Willebrand syndrome with pulmonary stenosis — warranting hemostatic screening before surgery. Severe/obstructive HCM refractory to standard therapy is managed with off-label MEK inhibition (trametinib) or mTOR inhibitors. Cancer surveillance follows RASopathy guidelines.

"Daily growth hormone (GH) injections are indicated for the treatment of short stature in children with Noonan syndrome" — PMID: 41774755

"Nearly 40% of patients with the Noonan syndrome had a bleeding diathesis and >90% of them had platelet function and/or coagulation abnormalities" — PMID: 24753526

The 15 Disease-Characteristic Domains

1. Disease Information

Overview. NS11 is a rare autosomal-dominant developmental disorder within the RASopathy family (disorders of RAS–MAPK dysregulation). It is the MRAS-related form of Noonan syndrome, characterized by classic Noonan features plus a characteristically severe, frequently neonatal/infantile hypertrophic cardiomyopathy.

Key identifiers. - OMIM: #618499 (Noonan syndrome 11) - MONDO: 0032786 - Gene: MRAS (HGNC:7227), 3q22.3; Ensembl ENSG00000158186; gene OMIM 608435 - RefSeq: NM_001085049.3 - ICD-10: Q87.1 (congenital malformation syndromes predominantly affecting stature) — code used for Noonan syndrome broadly; ICD-11: LD2F.11 (Noonan syndrome and Noonan-related syndromes) - MeSH: Noonan Syndrome (D009634) — no NS11-specific MeSH term - Orphanet: Noonan syndrome (ORPHA:648) — no separate NS11 subtype code

Synonyms/alternative names. Noonan syndrome 11; NS11; MRAS-related Noonan syndrome; M-Ras/R-Ras3–related Noonan syndrome.

Data source type. Information is derived from aggregated disease-level resources (OMIM, ClinVar, gnomAD) and from individual patient case reports (the handful of published NS11 cases), not from EHR-scale cohorts — reflecting the ultra-rare nature of the disease.

2. Etiology

Causal factor. Purely genetic: de novo germline activating missense variants in MRAS. No environmental or infectious cause.

Genetic risk factors. The disease-causing variants are themselves the sole "risk factor." Recurrent hotspots: p.Gly23Val, p.Gly23Arg, p.Thr68Ile, p.Gln71Arg (and likely-pathogenic p.Pro120Leu). MRAS is highly constrained (missense Z = 3.16, pLI = 0.99), so any missense change at a conserved GTP-handling residue is likely deleterious. No NS11-specific modifier genes are established.

Environmental risk factors. None known. As with all de novo dominant conditions, advanced paternal age is a general (inferred) risk factor for de novo point mutations, not specifically demonstrated for MRAS.

Protective factors. None identified. Given strong purifying selection at MRAS, no protective alleles are documented.

Gene–environment interactions. None established. NS11 is a monogenic, fully genetically determined condition.

3. Phenotypes

NS11 shares the core Noonan phenotype, with cardiac hypertrophy as the distinguishing severe feature. Frequencies below are largely extrapolated from broader NS and RASopathy-HCM literature given the tiny NS11 case count.

Phenotype HPO term Type Onset Frequency (NS11 cases / NS overall) Severity
Hypertrophic cardiomyopathy HP:0001639 Clinical sign (imaging) Neonatal/infantile Uniform in MRAS cases; ~20% of NS Severe, often life-threatening
Distinctive facies (hypertelorism, ptosis, low-set ears) HP:0000316, HP:0000508 Physical Congenital Typical of NS Variable
Short stature HP:0004322 Physical Postnatal Common Moderate
Developmental delay / learning difficulty HP:0001263 Behavioral/cognitive Childhood Common Variable
Pulmonary valve stenosis HP:0001642 Clinical sign Congenital Common in NS; seen in NS-HCM Variable
Webbed/broad neck HP:0000465 Physical Congenital Common Mild
Bleeding diathesis HP:0001892 Laboratory/clinical Any ~40–65% of NS Mild–moderate
Cryptorchidism (males) HP:0000028 Physical Congenital Common Mild
Lymphatic dysplasia / chylothorax HP:0000112, HP:0010288 Clinical Neonatal/infantile Subset Can be severe
Feeding difficulties HP:0011968 Clinical Neonatal ~50% of NS Usually transient

Quality-of-life impact. Dominated by cardiac morbidity (heart-failure symptoms, exercise intolerance, procedural risk), short stature, and neurodevelopmental/learning needs. Bleeding tendency complicates surgery. Formal EQ-5D/SF-36 data specific to NS11 are not available.

4. Genetic/Molecular Information

5. Environmental Information

Not applicable. NS11 is a monogenic de novo dominant disorder. No environmental factors, lifestyle factors, or infectious agents are implicated in causation or triggering. Standard cardiac-risk lifestyle considerations apply generically to any HCM patient but are not disease-specific.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

  1. A de novo germline missense variant in MRAS (e.g., c.68G>T, p.Gly23Val) alters a conserved GTP-binding/hydrolysis residue → impairs intrinsic and GAP-stimulated GTP hydrolysis (demonstrated; ~40-fold increased activation for p.Gly23Val).
  2. Impaired hydrolysis → M-Ras accumulates in the constitutively active, GTP-bound state with constitutive plasma-membrane targeting and prolonged non-raft localization (demonstrated).
  3. Active GTP–M-Ras → enhanced binding to the SHOC2–PP1c (PPP1CB) holophosphatase (demonstrated: enhanced binding to PPP1CB and SHOC2).
  4. SHOC2–PP1c → dephosphorylates the inhibitory Ser259 site of RAF → relieves 14-3-3-mediated RAF autoinhibition (demonstrated for the M-Ras–SHOC2–PP1c module).
  5. RAF activation → hyperactivation of the MEK→ERK (MAPK) cascade (demonstrated: increased MAPK signaling), with a branch to increased PI3K–AKT signaling (demonstrated, variable).
  6. ERK/AKT hyperactivation in developing tissues → dysregulated cell proliferation, differentiation, growth, and survival (inferred from RASopathy biology).
  7. In cardiomyocytes → cardiomyocyte hypertrophy, hypertrophic gene-expression program, and impaired Ca²⁺ handling (demonstrated in iPSC-CMs; variant necessary and sufficient) → hypertrophic cardiomyopathy (clinical manifestation).
  8. In craniofacial, skeletal, hematopoietic, lymphatic, and neural lineages → distinctive facies, short stature, bleeding diathesis, lymphatic dysplasia, and developmental delay (inferred by analogy to other RASopathies).
  MRAS missense (Gly23/Thr68/Gln71)
            │  impairs GTP hydrolysis
            ▼
  Constitutive GTP–M-Ras  ── membrane-targeted, non-raft
            │  enhanced binding
            ▼
      SHOC2 – PP1c (PPP1CB) holophosphatase
            │  dephosphorylates RAF-pSer259
            ▼
        RAF (relieved autoinhibition)
            ├──────────────► MEK ──► ERK  (MAPK; main axis)
            └──────────────► PI3K ──► AKT  (variable branch)
                                   │
                                   ▼
          cardiomyocyte hypertrophy + Ca²⁺ dyshandling
                                   │
                                   ▼
                 SEVERE HYPERTROPHIC CARDIOMYOPATHY
        (+ facies, short stature, bleeding, lymphatic, DD)

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Mechanistic Model / Interpretation

NS11 is mechanistically among the best-understood RASopathies at the "single-variant → single-phenotype" level, despite its rarity. The unifying model is constitutive RAS–MAPK activation driven by a hydrolysis-dead M-Ras GTPase that hyperengages the SHOC2–PP1c–RAF module. Three lines of orthogonal evidence converge:

Evidence layer Method Result Reference
Genetics Trio WES / targeted sequencing Recurrent de novo MRAS hotspots (Gly23, Thr68, Gln71) in NS-HCM PMID: 28289718, PMID: 31108500
Biochemistry GTP-loading, binding, signaling assays ~40× activation; impaired GTPase; ↑SHOC2/PPP1CB binding; ↑MAPK/PI3K-AKT PMID: 28289718, PMID: 31108500
Cell model CRISPR-isogenic iPSC-CMs Variant necessary and sufficient for hypertrophy + Ca²⁺ defects PMID: 31638832
Pathway anchor Effector reconstitution SHOC2–PP1c dephosphorylates RAF-Ser259 to activate RAF PMID: 16630891

The therapeutic corollary is direct: because the phenotype is driven by MEK/ERK output, pharmacologic MEK inhibition is a mechanism-matched therapy, and multiple RASopathy case reports (RIT1, RAF1, PTPN11) show that trametinib can reverse severe HCM and lymphatic disease — a strong rationale for its use in NS11, pending genotype-specific data.

Evidence Base

PMID Title (abbrev.) Contribution
28289718 Elucidation of MRAS in NS (Higgins 2017) First NS11 case; p.Gly23Val; ~40× activation; MD simulations
31108500 Activating MRAS mutations cause NS with HCM (Motta 2020) Two further cases (Thr68Ile, Gly23Arg); GTPase/SHOC2/PPP1CB mechanism
31638832 iPSC-CM CRISPR study (Higgins 2019) Variant necessary & sufficient for cardiomyocyte hypertrophy
16630891 Shoc2–PP1c M-Ras effector (Rodriguez-Viciana 2006) Defines SHOC2–PP1c → RAF-Ser259 mechanism
34776080 R-HCM review (Lioncino 2022) Severe R-HCM phenotype (CHF, LVOT obstruction)
29525650 RASopathy HCM natural history (Calcagni 2018) Early-onset severe HCM; mTOR-inhibitor rationale
38432396 MEK inhibition for RASopathy HCM (Chaput 2024) Therapeutic repurposing framework
42610277 Rigosertib reverses HCM in NS Dual RAS/MAPK+PI3K/AKT inhibitor efficacy (RAF1 model)
23312968 Noonan syndrome review (Roberts 2013) Core multisystem NS phenotype and prevalence
36394128 RASopathy genetics update (Tartaglia 2022) >20 genes; panel/exome testing rationale
18977283 M-Ras evolution (Keduka 2009) Single conserved orthologue; neural function
17538012 M-Ras–RA-GEF-2–Rap1 (Yoshikawa 2007) Secondary M-Ras effector branch
41774755 Somapacitan RCT in NS GH therapy for short stature
24753526 Hemostatic abnormalities in NS (Artoni 2014) ~40% bleeding diathesis; pre-surgical screening
22985731 Acquired vWS in NS (Wiegand 2012) Shear-related bleeding with pulmonary stenosis
12754583 Hematological findings in NS (Bertola 2003) Factor XI deficiency, platelet dysfunction

Limitations and Knowledge Gaps

  1. Tiny case count. Only a handful of molecularly proven NS11 patients are published. All frequency, penetrance, expressivity, and prognosis statements beyond "HCM is characteristic and severe" are extrapolated from broader NS/RASopathy cohorts, not from NS11-specific data.
  2. No NS11-specific epidemiology. Prevalence, incidence, sex ratio, and survival are not directly measured.
  3. No dedicated in vivo model. The definitive model is iPSC-CMs; a Mras knock-in mouse recapitulating the systemic phenotype is not published — limiting study of extra-cardiac features and whole-organism drug testing.
  4. Genotype-specific therapy data absent. MEK-inhibitor efficacy is documented in other RASopathy genotypes (RIT1, RAF1, PTPN11) but not yet specifically in MRAS patients; efficacy is inferred from shared downstream mechanism.
  5. Extra-cardiac mechanism largely inferred. The causal steps from ERK hyperactivation to facies, stature, lymphatic, and neurodevelopmental features are inferred by analogy, not demonstrated in MRAS tissue.
  6. No episignature/epigenetic, proteomic, metabolomic, or lipidomic profiling specific to NS11.
  7. p.Pro120Leu and p.Gln71Arg have less functional characterization than the Gly23/Thr68 hotspots.

Proposed Follow-up Experiments / Actions

  1. International case registry. Aggregate all molecularly confirmed MRAS patients (GeneMatcher/collaborative networks) to define true frequency, phenotypic range, cardiac natural history, and mortality.
  2. Generate an Mras knock-in mouse (e.g., p.Gly23Val) to model the systemic phenotype, test MEK/mTOR/rigosertib in vivo, and study extra-cardiac mechanisms.
  3. Genotype-specific trametinib data. Prospectively capture MEK-inhibitor response in MRAS patients within trials such as NCT06555237; report cardiac imaging and biomarker endpoints.
  4. Functional characterization of p.Gln71Arg and p.Pro120Leu (GTP loading, SHOC2/PPP1CB binding, MAPK/PI3K-AKT output) to confirm gain-of-function and refine ACMG classification.
  5. iPSC-CM drug screens comparing trametinib, mTOR inhibitors, rigosertib, and SHOC2/PPP1CB-directed strategies on MRAS-mutant cardiomyocytes; test rescue of Ca²⁺ handling.
  6. Structural studies / AlphaFold-informed modeling of mutant M-Ras–SHOC2–PP1c to identify the interface for potential allosteric inhibitors.
  7. Episignature analysis of MRAS patients to determine whether NS11 carries a distinguishing DNA-methylation signature useful for VUS resolution.

Report compiled from 5 investigation iterations, 8 confirmed findings, and 61 reviewed papers. Evidence types: human clinical (case reports/cohorts), in vitro (iPSC-CMs, biochemistry), model organism (ascidian, PC12; pathway-level mouse models), and computational (molecular-dynamics, constraint metrics).